Evidence map›Paper›PMID 36135065›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

Intrafraction Prostate Motion Management for Ultra-Hypofractionated Radiotherapy of Prostate Cancer.

Christoph Oehler, Nina Roehner, Marcin Sumila, Jürgen Curschmann, Fabrizio Storelli, Daniel Rudolf Zwahlen, Uwe Schneider

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Christoph OehlerDepartment of Radiation Oncology, Hospital Winterthur, 8400 Winterthur, Switzerland.
Nina RoehnerDepartment of Radiation Oncology, Hirslanden Zurich, 8032 Zurich, Switzerland.
Marcin SumilaDepartment of Radiation Oncology, Hirslanden Zurich, 8032 Zurich, Switzerland.
Jürgen CurschmannDepartment of Radiation Oncology, Hirslanden Zurich, 8032 Zurich, Switzerland.
Fabrizio StorelliDepartment of Radiation Oncology, Hirslanden Zurich, 8032 Zurich, Switzerland.
Daniel Rudolf ZwahlenDepartment of Radiation Oncology, Hospital Winterthur, 8400 Winterthur, Switzerland.ORCID 0000-0003-4359-7735
Uwe SchneiderDepartment of Radiation Oncology, Hirslanden Zurich, 8032 Zurich, Switzerland.
Klinik Hirslanden · CHKantonsspital Winterthur · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Determine the time-dependent magnitude of intrafraction prostate displacement and a cutoff for the tracking decision. Methods: Nine patients with localized prostate cancer were treated with ultra-hypofractionated radiotherapy (CyberKnife) with fiducial markers. Exact tract kV/kV imaging was used with an average interval of 19−92 s. A Gaussian distribution was calculated for the x-, y-, and z-directions (σx,y,z). The variation of prostate motion (μσ) was obtained by averaging the patients’ specifics, and the safety margin was calculated to be MAB = WYm + WBSs. Results: The calculated PTV safety margins were as follows: at 40 s: 0.55 mm (L/r), 0.85 mm (a/p), and 1.05 mm (s/i); at 60 s: 0.9 mm (L/r), 1.35 mm (a/p), and 1.55 mm (s/i); at 100 s: 1.5 mm (L/r), 2.3 mm (a/p), and 2.6 mm (s/i); at 150 s: 1.9 mm (L/r), 3.1 mm (a/p), and 3.6 mm (s/i); at 200 s: 2.2 mm (L/r), 3.8 mm (a/p), and 4.2 mm (s/i); and at 300 s: 2.6 mm (L/r), 5.3 mm (a/p), and 5.6 mm (s/i). A tracking cutoff of 2.5 min seemed reasonable. In order to achieve an accuracy of < 1 mm, tracking with < 50 s intervals was necessary. Conclusions: For ultra-hypofractionated radiotherapy of the prostate with treatment times > 2.5 min, intrafraction motion management is recommended.

Indexed as

Prostatic NeoplasmsRadiotherapy, Image-GuidedFiducial MarkersHumansMaleProstateIGRTMR-based adaptive radiotherapyprostate cancerprostate motionPTV marginradiation therapyradiopaque fiducial markerstereotactictrackingultra-hypofractionation

Identifiers

PMID36135065
PMCPMC9497512
OpenAlexW4294142630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.